Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer
2025/06/04 by Jing Yang, Xiaoning Yu, Mingming Xiao +9 · 26 citations
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Cancer, Lipids, and Metabolism #Histone Deacetylase Inhibitors Research #Immune cells in cancer
paper · doi:10.1136/gutjnl-2024-334361
Abstract
Background Pancreatic cancer exhibits limited clinical responses to immunotherapy, highlighting the need for new strategies to counteract its immunosuppressive microenvironment. Although metabolic reprogramming and epigenetic changes contribute to malignancy, the impact of lactate-driven histone lactylation on the tumour microenvironment (TME) has not been fully explored. Objective This study aims to investigate the role of histone lactylation in pancreatic cancer, focusing on its effects on cholesterol metabolism and antitumour immunity. Designs Global lactylome profiling was conducted to identify novel epigenetic mechanisms driven by lactate-induced histone lactylation. Mechanisms were investigated via RNA sequencing, CUT&Tag, immunoprecipitation-mass spectrometry and GST-pull down. Mass cytometry by time-of-flight, in vitro co-culture system, orthotopic pancreatic cancer models and flow cytometry were used to explore Acetyl-CoA acetyltransferase (ACAT2) functions. A proteolysis-targeting chimaera (PROTAC) was developed to degrade ACAT2. Results Global lactylome profiling revealed that lactate-driven histone lactylation, particularly H3K18la, promotes the transcriptional activation of ACAT2. ACAT2 acetylates mitochondrial carrier homolog 2 (MTCH2), stabilising it and disrupting oxidative phosphorylation, which increases lactate production and fuels a positive feedback loop in pancreatic cancer. This loop facilitates the delivery of cholesterol via small extracellular vesicles (sEVs), polarising tumour-associated macrophages toward an immunosuppressive M2 phenotype. Additionally, the PROTAC targeting ACAT2 enhanced the efficacy of immune checkpoint blockade therapy in vivo . Conclusions Our findings highlight the critical role of the H3K18la/ACAT2/sEV-cholesterol axis in TME reprogramming. Targeting this pathway may improve anti-PD-1 therapy response in pancreatic cancer, providing a novel therapeutic strategy by linking histone lactylation, cholesterol metabolic reprogramming and immune modulation.
Citations
Cited by
- Dual blockade of PD-1 and NKG2A prevents NK cell senescence and reprograms the immunosuppressive microenvironment in pancreatic cancer
- Epigenetic orchestration of cancer-immune dynamics: mechanisms, technologies, and clinical advancements. [europepmc]
- Lactylation in Tumor Immune Escape and Immunotherapy: Multifaceted Functions and Therapeutic Strategies. [europepmc]
- Lactylation as a cross-regulatory node in tumor metabolism and epigenetics: insights and therapeutic implications. [europepmc]
- From mechanism to targeted therapy: Advances in histone lactylation-driven cancer progression (Review). [europepmc]
- Lactylation-driven KRT19 promotes non-small cell lung cancer progression by suppressing cellular senescence. [europepmc]
- Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy. [europepmc]
- Lactylation in cancer: molecular mechanisms and advances in clinical study. [europepmc]
- Lactylation in colorectal cancer: Unveiling novel mechanisms in metabolism, progression and therapeutic targeting. [europepmc]
- Lactylation Converts ABHD6 into a Mitochondrial Regulator That Drives Lenvatinib Resistance in Hepatocellular Carcinoma. [europepmc]
- Lactylation and acetylation: parallel paths, divergent deeds, and research dilemmas. [europepmc]
- Protein lactylation: a metabolic signal driving cancer therapy resistance. [europepmc]
- Pancreatic cancer immunotherapy biomarkers: from traditional markers to multimodal integration and dynamic monitoring. [europepmc]
- Oncoprotein CYB561, acting in IRE1-XBP1-SREBF1 and FAK-ERK pathway, promotes breast cancer lipogenesis and progression. [europepmc]
- [Research progress on protein lactylation modification in malignant tumors]. [europepmc]
- The mechanism of PKM2/HIF-1α axis polarizing TAMs by upregulating glucose-serine metabolism to promote melanoma progression. [europepmc]
- Lactylation enzymes in cancer: Mechanisms and novel therapeutic approaches (Review). [europepmc]
- Three-dimensional-bioprinted stiff matrix triggers PDAC radioresistance through histone H3 lysine 18 lactylation (H3K18la) potentiates RAD51 activation. [europepmc]
- Lactylation modification in extracellular vesicles: A key regulator of cellular communication. [europepmc]
- p300: expanding beyond acetylation to mastermind lactylation-dependent tumorigenesis. [europepmc]
- Clinical implications of lactylation modification in digestive system tumors (Review). [europepmc]
- A pan-cancer atlas of metabolic regulatory circuitries integrating multi-omic, immune, and clinical dimensions. [europepmc]
- The trinity of T cell engagement: navigating the molecular and clinical landscape of CAR-T, TILs, and TCEs in the war against cancer. [europepmc]
- Lysine lactylation-mediated post-translational modification: Molecular mechanisms and therapeutic target exploration in tumour drug resistance. [europepmc]
- Case Report: Converting an immunologically “cold” tumor: exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma [europepmc]
- Research progress on the etiology and pathogenesis of pancreatic cancer: a narrative review [europepmc]
Related